Noctrix Health Granted FDA Breakthrough Device Designation for Wearable Restless Legs Syndrome Therapy

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Noctrix Health announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its wearable NTX100 Neuromodulation therapy designed for the treatment of adults with primary moderate-severe Restless Legs Syndrome (RLS) who are refractory to medications.

RLS is the second most common sleep disorder in the world and impacts over 10% of the adult population in the US, with an estimated 3 million cases each year and is mainly treated using dopaminergic drugs. Patients report painful sensations of tingling and an urge to move their feet which particularly worsens during evenings and nights. “Today, an estimated third of all RLS patients remain refractory or continue to have severe symptoms despite being on medications for years and that doesn’t even include the millions that cannot tolerate medication side-effects and would like an alternative,” said Allan May, member of Noctrix Health’s board of directors. Drugs, particularly dopaminergic ones, pose a high risk of “augmentation” of the condition especially with higher doses that are often required to treat moderate-severe RLS symptoms. Noctrix Health aims to treat RLS symptoms with its wearable neuromodulation platform that targets specific peripheral nerve fibers in a manner that is comfortable to wear to sleep.

The FDA Breakthrough Devices Program is a two-phase process intended to help patients receive timely access to breakthrough technologies that provide more effective treatment than the current standard of care for a life-threatening, or irreversibly debilitating disease. The treatment needs to have shown promising early clinical evidence that demonstrate an improvement over standard of care in order to be eligible for this designation. Shri Raghunathan, President & CEO of Noctrix Health, said: “We are thrilled that the FDA recognizes the promising potential that the therapy provides to millions of patients and very much look forward to working together with the agency during Phase 2 of this process to make this therapy available to patients expeditiously.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.